Alligator Bioscience to Address Immunogenicity with Epibase

Alligator Bioscience AB and AlgoNomics NV have announced that they have entered into a collaboration. AlgoNomics will employ its Epibase platform to complement Alligator Bioscience in the optimization of therapeutic proteins both in their internal projects and in collaborative projects with customers. The collaboration allows Alligator to maximally reduce immunogenicity upon optimization of protein therapeutics with their proprietary ssDNA recombination technology FIND.

Alligator Bioscience uses its proprietary FIND technology to develop new and optimize existing therapeutic and diagnostic proteins. Since 2001, Alligator Bioscience has successfully collaborated with several companies in the pharmaceutical, diagnostic and biotech industry, improving customers' proteins and helping them to build more competitive pipelines. The company has also created an internal pipeline of therapeutic drug candidates for major clinical indications, which are at varying stages of development.

For further information please contact:

Ann-Christin Malmborg Hager,

VP Business Development

Tel.: +46 46 286 4295

Email: anm@alligatorbioscience.com

Or visit: www.alligatorbioscience.com